State Street Corp Boosts Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

State Street Corp lifted its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 68.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,271,609 shares of the specialty pharmaceutical company’s stock after buying an additional 515,179 shares during the period. State Street Corp’s holdings in KalVista Pharmaceuticals were worth $14,725,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. nVerses Capital LLC purchased a new position in shares of KalVista Pharmaceuticals in the second quarter valued at about $25,000. China Universal Asset Management Co. Ltd. raised its position in KalVista Pharmaceuticals by 67.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock valued at $96,000 after purchasing an additional 3,328 shares during the last quarter. Intech Investment Management LLC purchased a new stake in KalVista Pharmaceuticals in the 3rd quarter worth approximately $126,000. SG Americas Securities LLC bought a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter worth approximately $153,000. Finally, Quest Partners LLC purchased a new position in shares of KalVista Pharmaceuticals during the third quarter valued at approximately $175,000.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ:KALV opened at $8.76 on Wednesday. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.97 and a 1 year high of $16.88. The company has a market cap of $432.90 million, a P/E ratio of -2.41 and a beta of 0.85. The stock’s fifty day moving average price is $10.25 and its 200-day moving average price is $11.59.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 8,077 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $74,793.02. Following the transaction, the insider now owns 94,199 shares of the company’s stock, valued at $872,282.74. The trade was a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Benjamin L. Palleiko sold 14,400 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $133,344.00. Following the completion of the sale, the chief executive officer now directly owns 266,598 shares of the company’s stock, valued at approximately $2,468,697.48. This trade represents a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,291 shares of company stock worth $304,086. Insiders own 10.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Bank of America assumed coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Finally, Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).